Cutaneous side effects of new antitumor drugs: clinical features and management.

摘要: Increased understanding of the pathogenesis malignant tumors has paved way for development new drugs medical tumor therapy. In addition to cytotoxic drugs, with specific molecular targets (so-called “targeted therapies”) and immunological therapeutic approaches are being implemented. Since an increasing number patients different types treated these doctors from various disciplines now faced dealing associated adverse events. The mechanisms action can lead clinically unusual novel events that targeted structure or mechanism, representing a major challenge. other organs, such also occur in skin. Cutaneous fact often forefront, example those epidermal growth factor receptor (EGFR) inhibitors mutated BRAF gene inhibitors. These changes dose treatment modality modification due their severity, painfulness, and/or psychological discomfort. At same time, incidence cutaneous be positive response, as observed EGFR Optimizing management is therefore crucial implementation success drug therapy many patients. This article summarizes current knowledge regarding presentation It based on evaluation selective analysis published articles Medline database, publications American Society Clinical Oncology (ASCO), authors’ experience. The data relating frequency events, particular, was Summary Product Characteristics controlled studies. However, since few randomized studies prophylaxis available, recommendations weaker evidence base (such case reports expert recommendations) have used.